Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Urology Annals, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to advancing the field of urology through high-quality research and clinical insights. Established in India in 2009, this journal serves as a vital platform for communication among urologists, researchers, and medical professionals, aiming to enhance understanding and innovation in urological sciences. With an ISSN of 0974-7796 and an E-ISSN of 0974-7834, the journal offers unrestricted access to its content, fostering knowledge dissemination and collaboration across the global medical community. Currently ranked in the Q3 category within urology and holding a Scopus rank of #79/120, Urology Annals showcases significant contributions that align with its mission to publish original research, reviews, and case reports that address contemporary challenges in urology. The journal's ongoing commitment to remaining a leading resource in the field is reflected through its convergence of years from 2010 to 2024, ensuring that it stays at the forefront of the latest urological advancements.

Urologia Journal, with ISSN 0391-5603 and E-ISSN 1724-6075, is a pivotal publication in the field of urology, published by SAGE Publications Ltd. Established in the United States, the journal has a rich historical foundation, with coverage spanning various periods beginning in 1947 and continuing to the present day, indicating its commitment to chronicling advancements in urological research and practice. As of 2023, the journal has achieved a respectable Q3 ranking in the field of Urology, reflecting its increasing influence and relevance among academic peers. Though not an open-access journal, it provides substantial value to its readers with rigorous peer-reviewed content that enhances the understanding and treatment of urological conditions. Researchers, clinicians, and students are encouraged to engage with the Urologia Journal to keep abreast of the latest findings and methodologies that contribute to better patient care and innovative therapeutic options in urology. As the field evolves, Urologia Journal remains committed to promoting quality scholarship and disseminating vital knowledge that shapes the future of urology.

Investigative and Clinical Urology is an esteemed open-access journal dedicated to advancing research and clinical practice in the field of urology. Published by the Korean Urological Association, this journal serves as a crucial platform for sharing innovative findings and discussions on urological science, treatments, and technologies. With an ISSN of 2466-0493 and an E-ISSN of 2466-054X, it has established its presence in the academic community since transitioning to open access in 2016. Positioned in the Q2 quartile of urology journals for 2023 and ranked 39th out of 120 in Scopus's urology category, it reflects a strong impact in the field with a 67th percentile ranking. This journal not only facilitates broad accessibility to high-quality research but also fosters collaboration and dialogue among researchers, professionals, and students interested in the latest advancements in urology. Operating from Seoul, South Korea, Investigative and Clinical Urology remains a pivotal resource for anyone seeking to enhance their understanding and practice in urological medicine.

EUROPEAN UROLOGY is a prestigious journal in the field of urology, published by Elsevier, and residing in the vibrant academic landscape of the Netherlands. Since its inception in 1975, the journal has made significant contributions to urological research, earning a top rank of #1 out of 120 in the Scopus category of Medicine - Urology, placing it within the esteemed 99th percentile of its field. With a commitment to disseminating cutting-edge research, clinical findings, and innovative practices, EUROPEAN UROLOGY has established itself as a pivotal resource for urologists and researchers alike. Although it does not offer open access options, it provides an indispensable platform for scholarly communication that drives advancements in patient care and medical knowledge. As the journal embarks on converged years leading up to 2024, it continues to strive for excellence in urology, welcoming contributions that reflect the latest scientific advancements and clinical applications.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

The Journal of Clinical Urology, published by SAGE Publications Ltd, is a prominent academic platform dedicated to advancing the field of urology and surgical medicine. With an ISSN of 2051-4158 and an E-ISSN of 2051-4166, this journal has been pivotal in disseminating cutting-edge research since its inception in 2008 and is set to continue through 2024. Although categorized in the Q4 quartile for both Surgery and Urology, and positioned in the 24th and 22nd percentiles respectively according to Scopus rankings, the journal remains an essential resource for professionals, researchers, and students who seek to understand clinical developments and innovative practices in urological surgery. While the journal does not operate under an Open Access model, it provides critical insights and valuable findings that significantly impact healthcare practices and patient outcomes in the urology field.

Prostate International is a leading open-access journal published by Elsevier Inc, dedicated to advancing research and knowledge in the field of urology, particularly focusing on prostate health and disease. Since its inception in 2013, the journal has preserved its commitment to disseminating high-quality, peer-reviewed articles that contribute significantly to clinical practices and scientific understanding. With an impressive Q1 ranking in urology and a current position as rank #35/120 among urology journals in Scopus, it occupies a prominent place in the academic landscape, ensuring that cutting-edge research reaches a broad audience. The journal's open-access policy enhances visibility and accessibility, fostering collaboration among researchers, healthcare professionals, and students. With the range of topics covered, from innovative treatments to diagnostic advancements, Prostate International serves as a vital resource for those committed to improving patient outcomes and driving the future of urological health.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.